MINNEAPOLIS, Jan. 10,
2025 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a
global leader in life science tools and reagents, today announced
the launch of new designer proteins engineered using advanced
Artificial Intelligence (AI) based design platforms and protein
evolutionary workflows. This expanded portfolio from Bio-Techne's
R&D Systems brand includes IL-2 Heat Stable Agonist, Activin A
Hyperactive, FGF basic Heat Stable (available both for research use
only (RUO) and made under good manufacturing processes (GMP) for
therapeutic development), as well as Wnt/RSPO1 Agonist, Wnt/RSPO2
Agonist, and Wnt/RSPO3 Agonist proteins.
These innovative recombinant proteins are designed and
engineered to address critical needs in cellular therapy workflows
and research applications, including improved cell culture
performance and optimized cell expansion. Leveraging generative AI
trained on data developed over almost five decades of proteomic
leadership, protein library evolution, and rational design,
Bio-Techne's expanded portfolio delivers next-generation cytokines
and growth factors with tailored functionalities such as
hyperactivity, enhanced receptor affinities, and improved heat
stability.
"Our growing portfolio of designer proteins combine cutting-edge
AI technology and innovative protein engineering," said
Will Geist, President, Protein
Sciences Segment. "This expanded portfolio empowers our customers
with versatile, high-performance solutions to boost the production
of immune cells and enhance regenerative medicine cell
therapies. Bio-Techne remains committed to developing the
tools and workflow solutions our customers need to advance
innovative cell therapies in both clinical and research
settings."
The new products include:
- IL-2 Heat Stable Agonist: Engineered with enhanced
thermal stability and altered receptor affinity for improved
biological activity, ideal for cellular therapy applications such
as CAR T-cell or Tumor-infiltrating lymphocytes (TIL)
expansion.
- Activin A Hyperactive: Optimized for superior
performance in regenerative medicine cell differentiation
applications.
- FGF basic Heat Stable: A robust and versatile growth
factor designed for improved protein stability and performance for
stem cell culture applications, available in both RUO and GMP
formats to support cell therapy manufacturing and advanced
research.
- Wnt/RSPO1, Wnt/RSPO2, and Wnt/RSPO3 Agonists: Key
reagents for advancing stem cell research, organoid development,
and regenerative medicine.
With this expanded portfolio, Bio-Techne continues to lead the
way in delivering disruptive innovations to the life sciences and
therapeutic development communities. Bio-Techne designer proteins
are available as part of our market leading R&D Systems branded
portfolio of proteins. For more information about these AI
Modified Proteins, visit our website.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH)
is a global life sciences company providing innovative tools and
bioactive reagents for the research and clinical diagnostic
communities. Bio-Techne products assist scientific investigations
into biological processes and the nature and progress of specific
diseases. They aid in drug discovery efforts and provide the means
for accurate clinical tests and diagnoses. With hundreds of
thousands of products in its portfolio, Bio-Techne generated
approximately $1.2 billion in net
sales in fiscal 2024 and has over 3,100 employees worldwide. For
more information on Bio-Techne and its brands, please visit
https://www.bio-techne.com or follow the Company on social
media at: Facebook, LinkedIn, Twitter or YouTube.
Contact: David Clair, Vice President, Investor Relations
& Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bio-techne-expands-rd-systems-ai-engineered-designer-protein-portfolio-to-advance-cell-therapy-and-regenerative-medicine-302347098.html
SOURCE Bio-Techne Corporation